Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARGiNAUT: AZD8965 in Idiopathic Pulmonary Fibrosis
NCT07652658Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Jun 2026
- Primary completion
- Sep 2028
- Countries
- 23
01
Overview
A Phase 2 trial of AZD8965 in idiopathic pulmonary fibrosis (IPF), sponsored by AstraZeneca. Started Jun 2026; status: recruiting.
02
Drugs
AZD8965
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT07652658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07652658.